PDCD1 and lung carcinoma: Here we conducted a prospective observational study of the prognostic potential of several existing and putative biomarkers of response to immunotherapy in a cohort of 85 patients with lung cancer (LC) receiving PD-1 or PD-L1 targeted immune checkpoint inhibitors (ICIs).